Isocitrate Dehydrogenase-Mutant Astrocytomas: Risk Stratification and Therapeutic Advance.

MedComm (2020) · 2026 · PMC13042621 · PMID 41930355

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Earlier trials (EORTC 26951; RTOG 9402) in anaplastic oligodendroglioma/oligoastrocytoma populations showed survival benefit with RT plus PCV—most prominently in 1p/19q‐codeleted tumors—with only a nonsignificant trend in IDH‐mutant, non‐codeleted subsets [ 119 , 120 , 121 ].

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.